Jakob Dupont - Mar 1, 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Signature
/s/ David Tucker, Attorney-in-Fact for Jakob Dupont
Stock symbol
ATRA
Transactions as of
Mar 1, 2022
Transactions value $
-$21,890
Form type
4
Date filed
3/3/2022, 06:02 PM
Previous filing
Feb 14, 2022
Next filing
May 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Award $0 +78.5K +86.66% $0.00 169K Mar 1, 2022 Direct F1
transaction ATRA Common Stock Sale -$21.9K -2.22K -1.31% $9.86 167K Mar 1, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Award $0 +148K $0.00 148K Mar 1, 2022 Common Stock 148K $10.21 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
F2 Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F3 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
F4 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.